Back to Journals » Journal of Pain Research » Volume 11

Sublingual sufentanil (Zalviso) patient-controlled analgesia after total knee arthroplasty: a retrospective comparison with oxycodone with or without dexamethasone

Authors van Veen DE, Verhelst CCWM, van Dellen RT, Koopman JSHA

Received 24 August 2018

Accepted for publication 2 November 2018

Published 14 December 2018 Volume 2018:11 Pages 3205—3210

DOI https://doi.org/10.2147/JPR.S185197

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Michael Schatman


David E van Veen,1 Christiaan CWM Verhelst,2 Roelof T van Dellen,3 JSHA Koopman4

1Erasmus University Rotterdam, Rotterdam, The Netherlands; 2Department of Orthopedic Surgery, Maasstad Hospital, Rotterdam, The Netherlands; 3Department of Hospital Pharmacy, Maasstad Hospital, Rotterdam, The Netherlands; 4Department of Anesthesiology, Maasstad Hospital, Rotterdam, The Netherlands

Abstract: Postoperative pain is a major problem, especially in orthopedic surgery. Our data suggest suboptimal pain management after total knee arthroplasty. This study evaluated a sufentanil sublingual tablet system (Zalviso) to optimize postoperative pain treatment. This retrospective, single-center, cohort study was conducted between January 2017 and September 2017. Zalviso as standard treatment was compared with a cohort receiving oxycodone (Oxy) immediate release and Oxy extended release and another receiving Oxy immediate release, Oxy extended release, and dexamethasone (Dexa + Oxy). The primary end point, pain intensity, was assessed on a numeric rating scale (NRS). Highest, lowest, and number of NRS scores >7 were collected. Secondary end points included length of hospital stay, nausea, and mobilization on the day of surgery. Patients receiving Dexa + Oxy had a lower lowest-pain intensity on day 0 (median 0, IQR 0–0) when compared to patients receiving Oxy (median 2, IQR 0–3; P<0.0001) or Zalviso (median 2, IQR 0–4; P<0.0001). No differences were observed on day 1 or 2. No differences were observed in highest pain score or number of patients reporting NRS scores > 7. Patients treated with Dexa + Oxy or Zalviso were discharged earlier compared to patients treated with Oxy (P<0.001). Patients treated with Zalviso experienced more nausea compared to other groups on day 0 and day 1 (P<0.001). Patients treated with Dexa + Oxy had a higher percentage of mobilization on the day of surgery compared to Oxy and Zalviso (P<0.001). In conclusion, Zalviso did not improve postoperative pain management in patients undergoing total knee arthroplasty and increased nausea.

Keywords: total knee arthroplasty, postoperative pain, multimodal treatment, acute pain, Zalviso, sublingual sufentanil tablet system, opioid, sufentanil, sublingual formulation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]